Published in Transplantation on April 15, 2000
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol (2012) 1.95
Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ (2014) 1.50
mTOR signaling for biological control and cancer. J Cell Physiol (2013) 1.40
Late kidney allograft loss: what we know about it, and what we can do about it. Clin J Am Soc Nephrol (2008) 1.11
Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol (2008) 1.06
Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg (2004) 1.04
Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol (2011) 1.04
Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep (2012) 0.98
Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant (2011) 0.98
Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg (2007) 0.94
Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function. Chem Res Toxicol (2009) 0.90
Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol (2013) 0.87
A review on therapeutic drug monitoring of immunosuppressant drugs. Iran J Basic Med Sci (2011) 0.83
Sirolimus-based calcineurin inhibitor withdrawal immunosuppressive regimen in kidney transplantation: a single center experience. Clin Exp Nephrol (2010) 0.82
Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients. J Am Soc Nephrol (2008) 0.82
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nat Rev Nephrol (2016) 0.82
Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol (2007) 0.80
Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions. Expert Opin Drug Metab Toxicol (2011) 0.80
Randomized exposure-controlled trials; impact of randomization and analysis strategies. Br J Clin Pharmacol (2007) 0.79
Ulcerative colitis after renal transplantation: A case report and review of literature. Indian J Nephrol (2011) 0.78
Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection. Ther Clin Risk Manag (2009) 0.78
Corticosteroid and calcineurin inhibitor sparing regimens in kidney transplantation. Nephrol Dial Transplant (2013) 0.78
Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany. Eur J Health Econ (2014) 0.77
Early experience with conversion to sirolimus in a pediatric renal transplant population. Pediatr Nephrol (2007) 0.77
Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects. Nephrol Dial Transplant (2008) 0.77
Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability. Ther Clin Risk Manag (2009) 0.76
New-onset diabetes after kidney transplant in children. Pediatr Nephrol (2014) 0.76
Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments. World J Urol (2007) 0.76
Cardiovascular risk factors following renal transplant. World J Transplant (2015) 0.75
Acute Hyperglycemia Associated with Anti-Cancer Medication. Endocrinol Metab (Seoul) (2017) 0.75
Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients. Br J Clin Pharmacol (2002) 0.75
A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation. J Transplant (2012) 0.75
Reviewing 15 years of experience with sirolimus. Transplant Res (2015) 0.75
Posttransplant Anemia as a Prognostic Factor of Mortality in Kidney-Transplant Recipients. Biomed Res Int (2017) 0.75
Analysis of liver function test abnormalities in kidney transplant recipients: 7 year experience. Pak J Med Sci (2017) 0.75
Relationships between sirolimus dosing, concentration and outcomes in renal transplant recipients. Br J Clin Pharmacol (2005) 0.75
Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. Medicine (Baltimore) (2017) 0.75
Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) N Engl J Med (2000) 8.02
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med (2013) 7.51
Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet (1993) 6.56
Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med (1993) 4.30
Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet (1997) 3.51
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant (2010) 3.35
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant (2007) 3.26
Activation of the cloned muscarinic potassium channel by G protein beta gamma subunits. Nature (1994) 3.21
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant (2000) 2.99
CC chemokine receptor 5 and renal-transplant survival. Lancet (2001) 2.82
Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation (1999) 2.81
Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet (2001) 2.76
Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect Immun (1992) 2.50
Seasonal changes in blood pressure in patients with end-stage renal disease treated with hemodialysis. N Engl J Med (1998) 2.34
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med (1999) 2.33
A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation (1999) 2.27
Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation (2000) 2.17
Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis (1999) 2.05
Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant (2010) 2.03
Experience with the Wujciak-Opelz allocation system in a single center: an increase in HLA-DR mismatching and in early occurring acute rejection episodes. Transpl Int (1998) 2.00
Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol (1994) 1.92
Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation (1997) 1.90
Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant (2012) 1.90
Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation (2001) 1.85
Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int (1993) 1.80
A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant (2014) 1.73
Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation (2000) 1.71
IMx tacrolimus II vs IMx tacrolimus microparticle enzyme immunoassay evaluated in renal and hepatic transplant patients. Clin Chem (1997) 1.67
Prevalence of IgA2 deposits in IgA nephropathies: a clue to their pathogenesis. N Engl J Med (1980) 1.67
Double versus single renal allografts from aged donors. Transplantation (2000) 1.58
Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy. Am J Transplant (2010) 1.54
Geographical prevalence, risk factors and impact of hepatitis B and C after renal transplantation. Clin Nephrol (2009) 1.51
Monitoring of immunoglobulin levels identifies kidney transplant recipients at high risk of infection. Am J Transplant (2012) 1.51
Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol (1993) 1.50
Safe preservation of human renal cadaver transplants by Euro-Collins solution up to 50 hours. Transplant Proc (1981) 1.50
Kidney-specific proteins in patients receiving aprotinin at high- and low-dose regimens during coronary artery bypass graft with cardiopulmonary bypass. Eur J Anaesthesiol (2005) 1.48
Practice variations in the evaluation of adult candidates for cadaveric kidney transplantation: a survey of the European Transplant Centers. Transplantation (2000) 1.46
Renal oncocytoma in a long-term renal-transplant recipient. Nephrol Dial Transplant (1995) 1.45
Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos (1991) 1.43
Valproate for epilepsy in renal transplant recipients receiving cyclosporine. Transplantation (1987) 1.42
The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther (1998) 1.42
Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol (1991) 1.42
Cyclosporin-induced muscular toxicity. Lancet (1990) 1.41
Acute renal failure after use of diesel fuel as shampoo. Arch Intern Med (1977) 1.40
CMV infection in the donor and increased kidney graft loss: impact of full HLA-I mismatch and posttransplantation CD8(+) cell reduction. Am J Transplant (2013) 1.40
Kidney graft dysfunction after drug interaction between clarithromycin and cyclosporin. Nephrol Dial Transplant (1996) 1.40
Relationship between calcineurin inhibition and plasma endothelin concentrations in cyclosporine-A-treated kidney transplant patients. Eur J Clin Pharmacol (2004) 1.39
[Bilateral Kienbock's disease in adolescents. Apropos of a surgically treated case]. Rev Chir Orthop Reparatrice Appar Mot (1992) 1.39
[Usefulness of HLA-DR expression in tubular cells of transplanted kidney for the diagnosis of rejection]. Med Clin (Barc) (1996) 1.39
Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine. Clin Nephrol (1988) 1.39
Serum alpha 2-macroglobulin in haemodialysis patients: baseline and kinetic studies. Nephrol Dial Transplant (1993) 1.39
Increased rate of renal transplant failure in patients with the G20210A mutation of the prothrombin gene. Am J Kidney Dis (2001) 1.38
Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int (1994) 1.38
Technetium-99m L,L-ethylenedicysteine clearance and correlation with iodine-125 orthoiodohippurate for the determination of effective renal plasma flow. Eur J Nucl Med (1996) 1.37
Systemic release and protective role of IL-10 in staphylococcal enterotoxin B-induced shock in mice. J Immunol (1994) 1.37
[ABO incompatible living donor kidney transplantation: a dream come true. Experience of Hospital Clínic of Barcelona]. Nefrologia (2009) 1.37
Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol (2002) 1.37
Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. J Clin Invest (1999) 1.35
Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc (1987) 1.35
The injection of deaggregated gamma globulins in adult mice induces antigen-specific unresponsiveness of T helper type 1 but not type 2 lymphocytes. J Exp Med (1992) 1.32
Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells. Immunology (1992) 1.32
Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant (2013) 1.31
Brucella endocarditis: the role of combined medical and surgical treatment. Rev Infect Dis (1990) 1.29
Mycobacterium haemophilum and mycobacterium xenopi associated infection in a renal transplant patient. Clin Nephrol (1985) 1.27
Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. Eur J Immunol (1990) 1.26
Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int (2000) 1.25
Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis. Clin Nephrol (1990) 1.24
The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther (2009) 1.22
Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant (2007) 1.22
Clinical pancreatic transplantation using the prolamine duct occlusion technique--the Munich experience. Transplant Proc (1987) 1.16
Improved survival in patients with insulin-dependent diabetes mellitus and end-stage diabetic nephropathy 10 years after combined pancreas and kidney transplantation. Transplantation (1999) 1.16
An outbreak of Ochrobactrum anthropi bacteraemia in five organ transplant patients. J Hosp Infect (1994) 1.16
Impaired lysosomal processing of beta2-microglobulin by infiltrating macrophages in dialysis amyloidosis. Kidney Int (1999) 1.15
Problems and issues with door-to-door, two-phase surveys: an illustration from central Spain. Neuroepidemiology (2001) 1.14
Acute adaptative changes to unilateral nephrectomy in humans. Kidney Int (1987) 1.12
Distribution of cell adhesion molecules (ICAM-1, VCAM-1, ELAM-1) in renal tissue during allograft rejection. Transplantation (1993) 1.11
Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol (1993) 1.10
Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit (2003) 1.10
In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A. J Exp Med (1993) 1.10
Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int (2001) 1.10
Physical performance does not improve in elderly patients following successful kidney transplantation. Nephrol Dial Transplant (1995) 1.09
High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol (1998) 1.09
Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. J Clin Invest (1996) 1.09
Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant (2007) 1.08
Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation (2001) 1.08
Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant (2006) 1.07
The irritable patient. Nephrol Dial Transplant (1998) 1.07
Metastatic pulmonary calcification after renal transplantation. Eur Respir J (1997) 1.07
Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem (2001) 1.06
Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 both in vitro and in vivo. J Immunol (1990) 1.06